The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells

Journal of Immunology

Volumn 166, Issue 3, 2001, Pages 1863-1870

  Alfano, M ^a   Vallanti, G ^a   Biswas, P ^a   Bovolenta, C ^a   Vicenzi, E ^a   Mantelli, B ^a   Pushkarsky, T ^a   Rappuoli, R ^a   Lazzarin, A ^a   Bukrinsky, M ^a   Poli, G ^a  

^a P2 P3 Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PERTUSSIS TOXIN; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BORDETELLA PERTUSSIS; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0035253575     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.3.1863     Document Type: Article

References (64)

1. Pharmacology of pertussis toxin PTX-B
2. The PTX-B of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains
3. Pertussis toxin activates protein kinase C and a tyrosine protein kinase in the human T cell line Jurkat
4. Bacterial toxins affect early events of T lymphocyte activation
5. Pertussis toxin triggers rapid second messenger production in human T lymphocytes
6. Identification of a 43-kilodalton human T lymphocyte membrane protein as a receptor for pertussis toxin
7. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: Role of Mac-1 (CD11b/CD18) and urokinase receptor (CD87)
8. Signaling mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: Role of tyrosine phosphorylation
9. Mechanism of pertussis toxin-induced myelomonocytic cell adhesion: Role of CD14 and urokinase receptor
10. Effect of bacterial toxins on human B cell activation. I. Mitogenic activity of pertussis toxin
11. Pertussis toxin effects on T lymphocytes are mediated through CD3 and not by pertussis toxin catalyzed modification of a G protein
12. The role of the S-1 and PTX-B components of pertussis toxin in its adjuvant properties for Th1 and Th2 cells
13. The binding subunit of pertussis toxin inhibits IL-1 induction of IL-2 and prostaglandin production
14. Pertussis toxin and target eukaryotic cells: Binding, entry, and activation
15. Properties of the B oligomer of pertussis toxin
16. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins
17. Rational design of vaccines
18. Genetically derived toxoids for use as vaccines and adjuvants
19. The lymphocytosis-promoting agent pertussis toxin affects virus burden and lymphocyte distribution in the SIV-infected rhesus macaque
20. A new classification for HIV-1
21. Chemokine receptors: Gateways to inflammation and infection
22. The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection
23. In vivo T lymphocyte origin of macrophage-tropic strains of HIV: Role of monocytes during in vitro isolation and in vivo infection
24. The neuropathogenesis of HIV-1 infection
25. Macrophages as a source of HIV during opportunistic infections
26. Immunologic effects of HIV in the lung
27. Viral dynamics in HIV-1 infection
28. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART
29. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: Replication is restricted at a postentry level
30. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
31. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate
32. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
33. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2
34. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency
35. Role of pro-inflammatory cytokines and β-chemokines in controlling HIV replication
36. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB
37. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat
38. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms
39. The B-oligomer of pertussis toxin inhibits HIV-1 replication at a multiple stages
40. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression
41. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
42. + T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation
43. 1.25-Dihydroxyvitamin D3 upregulates functional CXCR4 human immunodeficiency virus type 1 coreceptors in U937 minus clones: NF-κB-independent enhancement of viral replication
44. + cells express CXCR4 and its ligand stromal cell-derived factor-1: Implication for infection by T-cell tropic human immunodeficiency virus
45. A compilation and analysis of nucleic acid and amino acid sequences
46. A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-κB subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells
47. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo
48. 3′-azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
49. Strategies for antiviral therapy in AIDS
50. α interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells
51. Pseudotyping with human T-cell leukemia virus type 1 broadens the human immunodeficiency virus host range
52. Generation of high-titer pseudotyped retroviral vectors with very broad host range
53. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB
54. NF-κB-dependent and -independent pathways of HIV activation in a chronically infected T cell line
55. Pertussis toxin inhibits induction of human immunodeficiency virus type 1 in infected monocytes
56. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G
57. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage
58. HIV replication in IL-2 stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines
59. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G
60. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides
61. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines
62. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB
63. Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro
64. Inhibition of the HIV Rev transactivator: A new target for therapeutic intervention